Treatment Resistant Schizophrenia clinical trials

Explore recruiting treatment resistant schizophrenia clinical trials.

Recruiting treatment resistant schizophrenia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Treatment Resistant Schizophrenia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy with Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Poland

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine the efficacy, safety, and tolerability of fixed doses of 15 mg bid and 30 mg bid of evenamide as add-on in patients with documented treatment-resistant schizophrenia, which is not adequately controlled by a stable therapeutic dose of the patient’s current antipsychotic medication(s).

Hungary, France, Bulgaria, Spain, Germany, Croatia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Aripiprazole vs Paliperidone/Risperidone Using Multi-omics Data in Patients With a First Episode Psychosis

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Treatment Resistant Schizophrenia trials by city

Treatment Resistant Schizophrenia in Toronto Treatment Resistant Schizophrenia in Vancouver Treatment Resistant Schizophrenia in Montreal Treatment Resistant Schizophrenia in Calgary Treatment Resistant Schizophrenia in Edmonton Treatment Resistant Schizophrenia in Ottawa Treatment Resistant Schizophrenia in Winnipeg Treatment Resistant Schizophrenia in Quebec City Treatment Resistant Schizophrenia in Hamilton Treatment Resistant Schizophrenia in Kitchener Treatment Resistant Schizophrenia in London Treatment Resistant Schizophrenia in Halifax Treatment Resistant Schizophrenia in New York Treatment Resistant Schizophrenia in Los Angeles Treatment Resistant Schizophrenia in Chicago Treatment Resistant Schizophrenia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease